We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Three-Dimensional Growth Encourages Expression of Epigenetic Changes in Tumors

By LabMedica International staff writers
Posted on 26 Jan 2012
A team of biomedical engineers has found that growing cultures of cancer cells in two-dimensional Petri dishes fails to elicit epigenetic changes in the cells that occur when three-dimensional growth chambers are used.

In order to examine better the microenvironment surrounding a tumor, investigators at Tufts University (Boston, MA, USA) grew oral cancer cells in a three-dimensional model of lab-made tissue that mimicked the lining of the oral cavity.

They reported in the January 2012 issue of the journal Epigenetics that use of bioengineered human tissue constructs that mimic the complexity of their in vivo counterparts revealed that the tumor microenvironment could direct the reexpression of E-cadherin through the reversal of methylation-mediated silencing of its promoter. More...


Cadherins (named for “calcium-dependent adhesion”) are a class of type-1 transmembrane proteins. They play important roles in cell adhesion, ensuring that cells within tissues are bound together. They are dependent on calcium (Ca2+) ions to function, hence their name. It has been observed that cells containing a specific cadherin subtype tend to cluster together to the exclusion of other types, both in cell culture and during development.

Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.

Treating cancers to induce reexpression of E-cadherin through epigenetic control may be an important way to control cancer progression.

“Our findings show the reversible nature of E-cadherin when cancer cells are placed in a three-dimensional network of cells that mimics the way cancer develops in our tissues. This confirms that cancer biology needs to move into the “third dimension” where cancer cells can be studied in a network of other cells that can control their behavior. We know now that the plastic dish alone is not good enough,” said senior author Dr. Jonathan Garlick, professor of oral and maxillofacial pathology at Tufts University.

Related Links:
Tufts University





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.